ArticleHepatology communications2022
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease.
Article in Hepatology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06471686 (Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Pharmacological therapies for alcohol use disorder reduce hepatic decompensation & mortality in alcohol-related liver disease: A GRADE evaluation through a meta-analysis.The Indian journal of medical research · 2025Pooled it
- Treatment of alcohol use disorder in alcohol-associated liver disease: A meta-analysis.Hepatology communications · 2025Pooled it
- Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol-Associated Cirrhosis: NAL-CI Trial.Liver international : official journal of the International Association for the Study of the Liver · 2026Trial
- Virtual Reality-Based Cue Exposure and Aversion Therapy for Alcohol Dependence: A Randomized Controlled Trial.Addiction biology · 2026Trial
- Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2025Trial
- Exploratory associations between co-occurring opioid and alcohol use disorders and GIP/GLP-1 receptor agonist treatment.Communications medicine · 2026Article
- Early liver transplantation in alcohol-associated liver disease-Evolution of practice, patient selection, management, and outcomes.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026Review
- Low dose naltrexone for fibromyalgia: case series demonstrating pain relief and other health benefits.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Severe Anion Gap Metabolic Acidosis From Isopropyl Alcohol and Alcoholic Ketoacidosis: A Diagnostic Challenge.Cureus · 2025Article
- Alcohol-associated liver disease: Natural history, management and novel targeted therapies.Clinical and molecular hepatology · 2025Review
- Alcohol-related liver disease.Gastroenterology report · 2025Review
- Monitoring and treatment of alcohol use disorder: an integrated multidisciplinary model.Metabolism and target organ damage · 2025Article
- Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies.Clinics in liver disease · 2024Review
- Safety of naltrexone in patients with cirrhosis.JHEP reports : innovation in hepatology · 2024Article
- Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action.Addiction science & clinical practice · 2024Review
- Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2024Article
- Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease.Hepatology communications · 2024Article
- Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.Clinical therapeutics · 2023Review
- Integrated Multidisciplinary Management of Alcohol-associated Liver Disease.Journal of clinical and translational hepatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naltrexone is an approved drug for management of alcohol use disorder (AUD), but data in patients with liver disease (LD) are limited. We aimed to evaluate the safety of naltrexone in those with LD. This is a retrospective cohort of adults with and without LD who were prescribed naltrexone for AUD from 2015 to 2019 in a safety-net setting. Naltrexone hepatic safety was determined by liver enzyme changes during and after compared to before naltrexone prescription as well as rates of subsequent hospitalization and death by Kaplan-Meier methods. Factors associated with hospitalization were examined by Cox regression. Of 160 patients prescribed naltrexone for AUD, 100 (63%) had LD and 47 (47%) of those with LD had cirrhosis (47% decompensated). The total cohort, LD, and cirrhosis groups had lower adjusted mean aspartate aminotransferase and alanine aminotransferase levels after versus before naltrexone prescription (p < 0.001). Two-year survival was 97.7% (95% confidence interval [CI], 84.6-99.7), 95.4% (95% CI, 82.8-98.8), 90.8% (95% CI, 73.5-97.0), and 81.3% (95% CI, 41.2-93.8) in those without LD, LD without cirrhosis, cirrhosis, and decompensated cirrhosis groups (p = 0.46), respectively. Alcohol-related 2-year hospitalization rates were 8.2% (95% CI, 2.7-24), 27.7% (95% CI, 16.6-44.0), 40.5% (95% CI, 24.8-61.6), and 41.7% (95% CI, 23.3-66.6) for the groups without LD, LD without cirrhosis, cirrhosis, and decompensated cirrhosis (p = 0.007), respectively. Independent predictors of subsequent hospitalization were LD, (hazard ratio [HR], 3.70; 95% CI, 1.19-11.51; p = 0.02), cirrhosis (HR, 5.16; 95% CI, 1.69-15.75), and shorter duration (≤30 days) of naltrexone prescription (HR, 2.50; 95% CI, 1.l2-5.20; p = 0.01). Conclusion: Naltrexone is safe to use in patients with underlying LD, including those with compensated cirrhosis. Although encouraging, more safety data are needed for those with decompensated cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.